Published in Childs Nerv Syst on September 06, 2017
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med (1994) 9.15
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol (2006) 8.27
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med (1994) 7.96
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med (2010) 6.37
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol (2006) 6.07
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 5.44
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation (2007) 5.05
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet (2010) 4.87
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med (1998) 4.68
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med (1987) 4.38
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Coronary-artery stents. N Engl J Med (2006) 4.13
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol (2005) 4.05
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 3.84
Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation (2007) 3.40
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation (2006) 3.08
Coronary artery stenting and non-cardiac surgery--a prospective outcome study. Br J Anaesth (2006) 3.08
Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med (1991) 2.97
Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation (2006) 2.75
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation (2001) 2.73
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation (2009) 2.62
Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation (2009) 2.47
Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40
Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation (2007) 2.31
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J (2006) 2.23
Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol (2009) 2.16
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation (2007) 2.15
Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol (2008) 2.11
Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol (2005) 2.00
Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol (2005) 1.88
Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation (2009) 1.88
Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J (2002) 1.88
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol (2008) 1.84
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation (2010) 1.78
Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol (2005) 1.73
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol (2005) 1.72
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol (2002) 1.62
Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv (2009) 1.54
Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost (2006) 1.54
Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol (2006) 1.52
Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation (2007) 1.50
One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging (2009) 1.34
Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation (1992) 1.33
Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation (2009) 1.21
In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. Circulation (1995) 1.16
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol (2008) 1.07
Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med (2009) 1.07
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv (2010) 1.01
Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation (2005) 1.00
Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J (2009) 1.00
Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention (2010) 0.99
Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv (2006) 0.98
Early stent thrombosis: past, present, and future. Circulation (2009) 0.96
Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol (2007) 0.95
Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res (2006) 0.92
Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. Eur Heart J (2008) 0.92
Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. Circ J (2009) 0.87
Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry. Catheter Cardiovasc Interv (2010) 0.86
Thrombosis and restenosis after stenting in failed angioplasty: comparison with elective stenting. Am Heart J (1994) 0.86
Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol (2005) 0.85
Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. JACC Cardiovasc Interv (2010) 0.84
The state of periprocedural antiplatelet therapy after recent trials. JACC Cardiovasc Interv (2010) 0.80
Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv (2010) 0.80
Angiographic predictors of recurrent stent thrombosis (from the Outcome of PCI for stent-ThrombosIs MultIcentre STudy [OPTIMIST]). Am J Cardiol (2010) 0.77
High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. Catheter Cardiovasc Interv (2008) 0.76
Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol (2005) 0.76
Why fetal neurosurgery? Childs Nerv Syst (2017) 0.75